Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: Implications for coronary intervention

Journal of Thrombosis and Thrombolysis

Volumn 13, Issue 3, 2002, Pages 161-165

  Aggarwal, Atul ^a   Sobel, Burton E ^a   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Bivalirudin; Enoxaparin; Platelets; Reactivity

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; DRUG DERIVATIVE; ENOXAPARIN; FIBRINOGEN RECEPTOR; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; PADGEM PROTEIN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; TIROFIBAN;

AGED; ARTICLE; BLOOD; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; METABOLISM; MIDDLE AGED; THROMBOCYTE ACTIVATION; ADULT; ANTICOAGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EXPOSURE; DRUG PROTEIN BINDING; FEMALE; HUMAN CELL; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADENOSINE DIPHOSPHATE; AGED; ANTICOAGULANTS; CORONARY ARTERIOSCLEROSIS; DRUG EVALUATION; ENOXAPARIN; FLOW CYTOMETRY; HEPARIN; HIRUDINS; HUMANS; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS;

EID: 0036624483     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020478923794     Document Type: Article

References (19)

1. Holmes MB, Howard DB, Sobel BE, Schneider DJ. Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999;95:75-82.
2. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Am J Cardiol 2000;85:491-493.
3. Schneider DJ, Tracy PB, Mann KG, Sobel BE. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997;96:2877-2883.
4. Farrell TP, Hayes KB, Sobel BE, Schneider DJ. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. Am J Cardiol 1999;83:770-774.
5. Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ. Sobel BE. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost Thromb Haemost 2001;85:309-313.
6. Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999;84:203-207.
7. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively: A determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001;104:181-186.
8. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
9. Rand MD, Lock JB, van't Veer C, et al. Blood clotting in minimally altered whole blood. Blood 1996;88:3432-3445.
10. Xia Z, Wong T, Liu Q, et al. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantification of binding to activated platelets and platelet aggregation. Br J Hematol 1996;93:204-214.
11. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
12. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable angina or postinfarction angina. N Engl J Med 1995;333:764-769.
13. Kabbani SS, Watkins MW, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy. J Thromb and Thrombolysis 2001;12:171-176.
14. Aggarwal A, Kabbani SS, Rimmer JM, et al. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease, a potential contributor to cardiovascular risk. Am J Kid Dis, in press.
15. Eika C. Inhibition of thrombin-induced aggregation of human platelets in heparin. Scand J Haematol 1971;8:216-222.
16. Thomson C, Forbes CD, Prentice CRM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 1973;45:485-494.
17. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Farreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:64-73.
18. Weitz J, Huboda M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
19. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet rich thrombi: role of platelet factor 4. Circulation 1990;82:1193-1202.